Screening & Enrollment

Column

Patients Screened, Approached, and Enrolled

Study Exclusions (% of All Patients Excluded)

Column

Cumulative Enrollment as of March 22, 2019

Enrolled Participants (Total: 510)

Patients characteristics

Control
(n=132)
Enzalutamide
(n=86)
Abiraterone
(n=109)
Carboplatin
(n=77)
Cabazitaxel
(n=72)
Docetaxel
(n=91)
Overall
(n=567)
age
Mean (SD) 75.1 (4.33) 75.0 (4.66) 75.0 (4.54) 75.0 (5.97) 75.5 (5.49) 74.8 (5.06) 75.1 (4.92)
Median [Min, Max] 75.0 [64.7, 90.9] 74.7 [66.4, 86.6] 75.2 [60.6, 83.9] 74.8 [61.5, 86.9] 76.6 [62.5, 88.1] 74.8 [64.3, 88.5] 75.1 [60.6, 90.9]
PSA
Mean (SD) 107 (152) 131 (153) 98.1 (142) 108 (150) 94.3 (167) 128 (181) 111 (157)
Median [Min, Max] 45.6 [0.00981, 711] 70.8 [0.0318, 684] 43.0 [0.00438, 720] 45.6 [0.00105, 687] 34.7 [0.0136, 1100] 58.4 [0.000527, 878] 48.5 [0.000527, 1100]
ctdna_frac
Mean (SD) 17.1 (22.2) 18.4 (22.3) 18.1 (24.1) 15.8 (21.4) 13.6 (14.8) 15.2 (21.9) 16.6 (21.6)
Median [Min, Max] 9.40 [0.229, 90.0] 9.36 [0.0493, 90.0] 8.07 [0.168, 90.0] 6.75 [0.0748, 90.0] 8.15 [0.212, 70.9] 5.90 [0.210, 90.0] 7.88 [0.0493, 90.0]
Bone.metastases
no 26 (19.7%) 21 (24.4%) 27 (24.8%) 15 (19.5%) 18 (25.0%) 13 (14.3%) 120 (21.2%)
yes 106 (80.3%) 65 (75.6%) 82 (75.2%) 62 (80.5%) 54 (75.0%) 78 (85.7%) 447 (78.8%)
visceral_met
no 106 (80.3%) 76 (88.4%) 97 (89.0%) 69 (89.6%) 61 (84.7%) 75 (82.4%) 484 (85.4%)
yes 26 (19.7%) 10 (11.6%) 12 (11.0%) 8 (10.4%) 11 (15.3%) 16 (17.6%) 83 (14.6%)

Prob signaturures

Prob subtypes